About this Research Topic
Pancreatic cancer is the 7th leading cause of death among neoplasms worldwide. The symptoms are nonspecific but include abdominal pain, nausea, weight loss, and loss of appetite. Since the curability and survival rates are very low, the quality of life for pancreatic cancer patients is significantly diminished. Many causes of pancreatic cancer are known, including smoking tobacco, age over 60, diabetes, family history, chronic pancreatitis, excessive alcohol consumption, obesity, and so on. However, the mechanism of pancreatic cancer occurrence is unclear and the anti-cancer drug for pancreatic cancer is limited.
Over the years, the genetic landscape of pancreatic cancer has been widely analyzed. Despite its low tumor mutational burden, several genes are frequently mutated, including KRAS, TP53, CDKN2A, and SMAD4. Furthermore, there are also more rarely altered genes that may potentially be associated with targeted therapeutical options, such as BRAF, FGFR1, MYC, MDM2, BRCA1 and 2, ATM, PALB2, and mismatch repair genes. Numerous trials have been carried out with novel target drugs, hoping to improve OS and response rates. In this Research Topic, we try to provide an in-depth analysis of both well-known and novel targets being explored in pancreatic cancer, including PARP, EGFR, HER2, KRAS and its downstream and upstream pathways, JAK/STAT pathway, angiogenesis, metabolisms, epigenetic targets, claudin, and novel targets, aim at developing new drug candidates and investigate the mechanisms.
We welcome Original Research, Review, and Mini-Review articles that highlight the latest advances in the mechanism of pancreatic cancer occurrence and the development of anti-cancer drug candidates. Topics of interest include but are not limited to the following:
- Research on the mechanism of drugs for pancreatic cancer
- Discoveries of new drug candidates, including natural products, for pancreatic cancer
- Identification of new drug targets for the diagnosis and therapy of pancreatic cancer
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Over the years, the genetic landscape of pancreatic cancer has been widely analyzed. Despite its low tumor mutational burden, several genes are frequently mutated, including KRAS, TP53, CDKN2A, and SMAD4. Furthermore, there are also more rarely altered genes that may potentially be associated with targeted therapeutical options, such as BRAF, FGFR1, MYC, MDM2, BRCA1 and 2, ATM, PALB2, and mismatch repair genes. Numerous trials have been carried out with novel target drugs, hoping to improve OS and response rates. In this Research Topic, we try to provide an in-depth analysis of both well-known and novel targets being explored in pancreatic cancer, including PARP, EGFR, HER2, KRAS and its downstream and upstream pathways, JAK/STAT pathway, angiogenesis, metabolisms, epigenetic targets, claudin, and novel targets, aim at developing new drug candidates and investigate the mechanisms.
We welcome Original Research, Review, and Mini-Review articles that highlight the latest advances in the mechanism of pancreatic cancer occurrence and the development of anti-cancer drug candidates. Topics of interest include but are not limited to the following:
- Research on the mechanism of drugs for pancreatic cancer
- Discoveries of new drug candidates, including natural products, for pancreatic cancer
- Identification of new drug targets for the diagnosis and therapy of pancreatic cancer
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords: pancreatic cancer, mechanism, drug targets, drug candidates
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
